Amgen's stock faced significant pressure today, closing down nearly 2% amid analyst downgrades and broader market turmoil.
Amgen Inc. (NASDAQ:AMGN) saw its shares decline by 1.77% in today's trading session, closing at CA$384.33. This drop was influenced by a downgrade from HSBC and ongoing market challenges.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$223.32B
P/E
25.0x
Div. yield
2.43%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+0.04%
Beta
0.41
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 9, 2026
Wall Street analysts forecast AMGN stock price to fall 3.9% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$391.46
-3.9% Upside
Previously C$390.94 on Oct 5, 2026
Current Price
C$407.44
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.1%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$487.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$432.43 | C$376.50 – C$496.67 |
| 60 trading days | C$458.95 | C$377.31 – C$558.25 |
| 90 trading days | C$487.10 | C$383.21 – C$619.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Amgen's stock struggles under the weight of analyst downgrades and increasing competition in the biopharma sector.
Amgen's stock tumbles 1.77% amid market pressures
The company’s market cap stands at approximately CA$211.53 billion, reflecting its significant presence in the biopharma industry despite current challenges.
Bull case
Amgen has a solid operational track record and a promising pipeline that could lead to growth opportunities, especially with upcoming clinical trial results on the horizon.
Bear case
The recent downgrade by HSBC raises concerns about limited near-term upside and growing competition from biosimilars that could impact Amgen's established products.
Advertisement
Analyst Downgrades Weigh on Amgen
HSBC downgraded Amgen from Buy to Hold, lowering its target price from $445 to $425. Analysts pointed out that while the stock has performed well operationally, it is now trading close to its target price, indicating limited near-term upside. This downgrade comes as the biopharma sector faces increased competition and a shift in investor focus towards companies with stronger growth potential.
Market Conditions Contribute to Decline
The broader market faced challenges today, with rising Treasury yields and geopolitical tensions affecting investor sentiment. The Nasdaq index closed down 0.64%, highlighting a tough environment for growth stocks like Amgen. As investors prepare for upcoming inflation data, uncertainty may continue to weigh on Amgen's stock in the near term.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
